Outside allogeneic stem cell transplant, treatment of patients with relapsed or refractory MCL is typically palliative and primarily includes covalent or non-covalent Bruton Tyrosine Kinase (BTK) inhibitors [8], lenalidomide, or Bcl-2 antagonists [9]. Here, BTK is linked to mantle cell lymphoma.